Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Palantirs strong quarterly results and raised outlook have been overshadowed by a post-earnings selloff, as traders focus on slower contract-booking growth and the stocks premium valuation. Bulls point to strong commercial AI demand and revenue growth, while bears question whether bookings can sustain the growth expectations priced into the shares.

Shopifys quarterly results sparked a sharp selloff as traders focused on revenue and GMV misses and moderating growth, despite stronger profit and cash flow; many see the reaction as excessive and point to a rebound, while bears argue the stocks high valuation leaves little room for disappointment.

A record quarterly report and raised fiscal-year outlook, supported by strong bookings and demand for AI-chip testing systems, drove AEHRs sharp rebound. Traders welcomed the results and see further AI-related growth potential, while skeptics question the valuation and whether the move can hold.

Madrigals Q3 results, including strong Rezdiffra growth and its first profitable quarter, are driving attention. Bulls emphasize the launch momentum and MASH market opportunity, while skeptics point to spending and uncertainty around future clinical-outcomes data, debating why the stock faded despite the results.

Fiservs rally follows a Q3 earnings and revenue beat, a doubled cost-savings target and a planned share buyback, offering relief after a prolonged selloff. Traders are debating whether the results and new management mark a genuine turnaround or merely a bounce, while some attribute the move to short covering.

Organigrams agreement to acquire Aurora, topping Curaleafs competing bid, has driven the sharp rally. Traders are debating whether Curaleaf could counter with a higher offer and whether the deal limits further upside; reactions range from welcoming the acquisition to calling for better terms.

A report that nonprofit Usona had filed for a psilocybin treatment for major depression sparked concern about competition and a sharp selloff, though traders dispute how confirmed the filing is and whether it threatens Compasss treatment-resistant-depression focus and commercial infrastructure. The debate is tempered by Compasss update that COMP360s FDA submission is nearing completion, with some traders viewing Usonas potential entry as manageable and others concerned about timing and market share.

MP is drawing attention as part of the volatile rare-earth and critical-minerals trade, with traders weighing U.S.China supply tensions against the strategic case for domestic production. Some cite MPs magnet deliveries and expansion plans as support, while others focus on the sector-wide selloff and execution risks.

MongoDBs CEO departure to Meta, announced immediately before Investor Day, sparked a sharp selloff and volatile trading. Traders are split between viewing the leadership uncertainty as a lasting risk and seeing the drop as an overreaction, pointing to reaffirmed guidance and former CEO Dev Ittycherias return as interim chief.

Luckins Q3 resultswith stronger operating profitability, expanding margins and record customer reachalongside a new share-repurchase program are driving attention. Bulls welcome the growth and buyback, while skeptics point to weak same-store sales and argue that OTC trading and uncertainty around a relisting are keeping the shares range-bound.